Iceland· IS-EU/1/16/1138/005-007
Venclyxto
A venetoclax product containing venetoclaxum inn, registered in Iceland by AbbVie Deutschland GmbH & Co. KG. The same ATC class is registered in 14 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Venetoclax is registered in 14 of 19 countries.
Countries holding a registration under ATC L01XX52 (venetoclax), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 9 of them publish a price we can compare per daily dose
Venetoclax · ATC L01XX52
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of venetoclax costs, country by country.
Normalised to the WHO defined daily dose (0.4 g), the median price runs from $226.72 in Switzerland to $1527.13 in France — a ×6.7 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Venetoclax · price per daily dose (0.4 g)
USD · FX 28 Sept 2026
- FR France$1527.13
- CH Switzerland$226.72
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Venetoclaxum INN
- Manufacturer
- AbbVie Deutschland GmbH & Co. KG
- Country
- Iceland (IS)
- ATC code
- L01XX52
- ATC class
- Venetoclax
- Defined daily dose
- 0.4 g, O
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 3
3 priced- ean5387767 stk x1 pakkiISK 80130
- ean52854214 stk x1 pakkiISK 157231
- ean532535112 stk x1 þpakkiISK 728881
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
338 interactions on record for venetoclax.
Graded by severity as the source publishes them — 168 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Venetoclax · interactions on record
338 records
- 168 severe
- 168 moderate
- 2 minor
Most severe, free to view
- AprepitantA04AD12severe
- RolapitantA04AD14severe
- FidaxomicinA07AA12severe
- EliglustatA16AX10severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Venetoclax in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandVenclyxtoAbacus Medicine A/S
- CzechiaVENCLYXTOAbbVie Deutschland GmbH & Co.KG, Ludwigshafen
- SpainVENCLYXTO 100 MG COMPRIMIDOS RECUBIERTOS CON PELICULAAbbvie Deutschland Gmbh & Co. Kg
- SwitzerlandVenclyxto 100 mg, FilmtablettenAbbVie AG
- NorwayVenclyxtoAbacus Medicine A/S
- SwedenVenclyxto 100 mg Filmdragerad tablettAbbVie Deutschland GmbH & Co KG
- BelgiumVenclyxto 100 mgAbbVie Deutschland
- United StatesVenclextaAbbVie Inc.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Venclyxto
- Liechtenstein · Venclyxto
- Norway · Venclyxto
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d7231a34-d130-420b-83ee-079b7d5f729b GET /v1/drugs/d7231a34-d130-420b-83ee-079b7d5f729b?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Filmuhúðuð tafla",
"source": "lyfjastofnun",
"atc_raw": "L01XX52",
"marketed": true,
"strength": "100 mg",
"ma_number": "EU/1/16/1138/005-007",
"substance": "Venetoclaxum INN",
"other_info": "Ávísun lyfsins er bundin við sérfræðinga í blóðsjúkdómum.",
"legal_status": "(R Z) Sérfræðingsmerkt (og lyfseðilsskylt)",
"ma_issued_serial": "42709"
}See everything about venetoclax.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.